A self-injected smart drug holds out new hope for migraine sufferers who until now have had to grit their teeth and bear the pain of thunderclap headaches.
Trial results show that the antibody drug erenumab can cut episodic migraine attacks by more than half in a large proportion of cases.
The drug, administered with a self-injection device similar to those used by diabetics, was tested on patients who had failed to respond to up to four other treatments.
READ MORE: Children with ADHD being excluded up to six times on average amid learning support cuts
Trial leader Dr Uwe Reuter, from The Charite-University Medicine Berlin in Germany, said: "The people we included in our study were considered more difficult to treat, meaning that up to four other preventative treatments hadn't worked for them.
"Our study found that erenumab reduced the average number of monthly migraine headaches by more than 50% for nearly a third of study participants.
"That reduction in migraine headache frequency can greatly improve a person's quality of life."
Migraine is a neurological disorder marked by headaches that range in severity from moderate to blindingly painful.
Other symptoms include nausea and light sensitivity. Each day, an estimated 200,000 people in the UK experience a migraine attack.
Attacks can last anything from four hours to three days and may prevent the sufferer from going to work or participating in normal activities.
People affected by episodic migraine may have up to 14 headache days a month.
For the Phase III Liberty trial, 246 migraine sufferers were given injections of erenumab or a dummy placebo drug once a month for three months.
Of the participants, 39% had been treated unsuccessfully with two other medications, 38% with three medications and 23% with four medications.
Erenumab, marketed by the global drug company Novartis under the brand name Aimovig, is not yet licensed for use in the UK.
READ MORE: Breakthrough hope as Scots scientists identify depression genes
Dr Mark Toms, Chief Scientific Officer at Novartis UK, said: "There has been no real advancement in migraine treatment for the past 20 years and we're proud to be breaking new ground in neurology for the millions of people in the UK living with the painful and disruptive symptoms of migraine.
"Whilst these data further reinforce erenumab's efficacy and safety profile it also highlights the clear unmet need that exists for targeted migraine prophylactic treatment and we are committed to working closely with the relevant regulatory bodies to make erenumab available to those that need it as soon as possible."
The drug works by targeting and blocking a pain-signalling molecule in the brain called calcitonin gene-related peptide (CGRP).
The findings will be presented at the American Academy of Neurology's annual meeting taking place in Los Angeles from April 21 to 27.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here